Riskpilot← Back to searchSign inGet full accessNORWEGIAN MYCELIUM AS
ASActiveOrg 9259957623 Ullevålsveien 68 Bygg 2, 0454 OsloIndustrial product and fashion design activities · NACE 7411Est. 202012 employees
Revenue 2024
NOK 6,7M
+854% vs 2023
EBITDA margin
-128.3%
+1% vs 2023
Equity ratio
62.9%
Financial strength
Net profit 2024
NOK -10,1M
-8% vs 2023
| Revenue | NOK 6,7M | +854% |
| EBITDA | NOK -8,6M | +1% |
| Net profit | NOK -10,1M | -8% |
| Total assets | NOK 10,6M | +53% |
| Equity | NOK 6,7M | +28% |
| Employees | 12 | — |
Legal name
NORWEGIAN MYCELIUM AS
Org number
925995762
Legal form
Aksjeselskap
NACE code
7411 · Industrial product and fashion design activities
Founded
2. desember 2020
Share capital
NOK 53 529
Employees
12 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Forskning og utvikling av bærekraftige materialer og nye kilder til protein.
Address
3 Ullevålsveien 68 Bygg 2, 0454 Oslo
Email
info@nomy.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 1 101 | 1 339 | 704 | 6 716 |
| Staff expenses | −1 502 | −3 624 | −6 052 | −9 124 |
| EBITDA | −1 204 | −4 208 | −8 696 | −8 619 |
| Depreciation & amort. | −0 | −270 | −620 | −1 544 |
| EBIT | −1 204 | −4 478 | −9 316 | −10 163 |
| Net financials | −0 | −24 | −26 | 35 |
| Profit before tax | −1 205 | −4 502 | −9 342 | −10 128 |
| Tax | 7 | −0 | −0 | −0 |
| Net profit | −1 212 | −4 502 | −9 342 | −10 128 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1 859 | 10 675 | 6 907 | 10 580 |
| Equity | 1 381 | 9 803 | 5 177 | 6 651 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 479 | 871 | 1 730 | 3 929 |
| Total debt | 479 | 871 | 1 730 | 3 929 |
EBITDA margin
-128.3%
This company
15.8%
Market median
-912% vs market
20212024
Equity ratio
62.9%
This company
38.2%
Market median
+65% vs market
20212024
Return on equity
-152.3%
This company
18.4%
Market median
-928% vs market
20212024
Net profit margin
-150.8%
This company
8.1%
Market median
-1962% vs market
20212024
Asset turnover
0.63×
This company
1.12×
Market median
-44% vs market
20212024
Debt / equity
0.59×
This company
0.62×
Market median
+5% vs market
20212024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ID Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2023 | |
| Board of Directors | 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 40.33% | 40.33% | 2022 | |
| Company | 33% | 33% | 2022 | |
| Company | 6.55% | 6.55% | 2022 | |
| Company | 4.08% | 4.08% | 2022 | |
| Company | 4.08% | 4.08% | 2022 | |
| Company | 2.45% | 2.45% | 2022 | |
| Company | 1.57% | 1.57% | 2022 | |
| Company | 1.02% | 1.02% | 2022 | |
| Company | 1.02% | 1.02% | 2022 | |
| Company | 1.02% | 1.02% | 2022 | |
| Company | 1.02% | 1.02% | 2022 | |
| Company | 1.02% | 1.02% | 2022 | |
| Company | 1.02% | 1.02% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Fiat Lux As
NORWEGIAN MYCELIUM AS Board members of NORWEGIAN MYCELIUM AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ingrid Dynna | Chief Executive Officer | 0 companies |
| Maren Hjorth Bauer | Chairman | 0 companies |
| David Andrew Quist | Board of Directors | 0 companies |